World Surgery Forum: IMPORTANT MCQ POINTS

Bailey Chapter 4 Based MCQs

Basic surgical skill and anastomoses

Which of the following is true statement regarding elliptical incisions ?

Two times as long as it is wide
Five times as long as it is wide
Four times as long as it is wide
Three times as long as it is wide

Answer: A

Rule of thumb for elliptical incisions: ‘an elliptical incision must be at least three times as long as it is wide’ for the wound to heal without tension.

Consider following statements regarding abdominal incisions :

Transverse incisions tend to be associated with fewer respiratory complications
Transverse incisions tend to be associated with better cosmetic outcome
Midline incisions tend to be associated with fewer respiratory complications
Midline incisions tend to be associated with better cosmetic outcome

Identify true statements from the following ?

Both 1 and 3 are true
Both 1 and 2 are true
Both 2 and 4 are true
Both 3 and 4 are true

Answer: B

Transverse incisions tend to be associated with fewer respiratory complications and a better cosmetic outcome.

In the past, traditionally vertical midline or paramedian incisions were used for the majority of abdominal procedures, but there is a current trend to utilise transverse incisions wherever possible as this minimises postoperative complications

5/07/2020 03:17:00 PM

Induction of apoptosis is either death receptor
dependent (extrinsic pathway) or independent (intrinsic pathway)

The two best understood death receptor pathways are the Fas receptor and death receptor 5 that bind the extracellular Fas ligand and TRAIL, respectively. (MCQ)

Cytochrome c is directly involved in the activation of caspase 9, which activates caspase 3, which then leads to apoptosis (MCQ)

Angiogenesis inhibitors are associated with specific tissues or circulate in the blood. These are interferon-α, thrombospondin, tumstatin, canstatin, endostatin, and angiostatin. (MCQ)

Most telling are the results of clinical studies with the anti-VEGF antibody bevacizumab (Avastin), the first angiogenesis inhibitor approved by the Food and Drug Administration for treatment of colon cancer. Bevacizumab significantly prolongs the survival of patients with advanced cancer. (MCQ)